UBS raises InnoCare Pharma stock price target to HK$25.20 on pipeline potential

Published 24/07/2025, 06:40
UBS raises InnoCare Pharma stock price target to HK$25.20 on pipeline potential

Investing.com - UBS raised its price target on InnoCare Pharma Limited (HK:9969) (OTC:INCPF) to HK$25.20 from HK$13.60 on Thursday, while maintaining a Buy rating on the stock.

The price target increase follows UBS’s recent visit to the company, which strengthened its outlook on InnoCare’s global research and development efforts and domestic commercialization strategy.

UBS highlighted multiple drug candidates in InnoCare’s pipeline showing increased global potential, specifically orelabrutinib for multiple sclerosis and mesutoclax for acute myeloid leukemia and myelodysplastic syndrome.

The firm noted positive market performance for orelabrutinib in China, where it achieved a 30% share among BTK inhibitors in April-May 2025, demonstrating commercial traction in its home market.

UBS identified several upcoming catalysts for InnoCare, particularly potential global partnerships expected to develop in the second half of 2025, as key factors supporting the significant price target increase.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.